---
title: "Amavita Research vs. Academic Medical Center Sites — Sponsor Decision Guide"
url: https://md.amavitaresearch.com/compare/amavita-vs-academic-medical-center-sites
canonical: https://www.amavitaresearch.com/compare/amavita-vs-academic-medical-center-sites
schema_type: WebPage
last_updated: 2026-05-13
---

# Amavita Research vs. Academic Medical Center Sites

How an independent investigator-led site differs from a typical U.S. academic medical center (AMC) clinical trial site — by criteria sponsors care about.

AMCs and independent investigator-led sites both run high-quality cardiovascular trials. They differ on contract execution speed, indirect cost rates, patient flow source, PI workload, and trial-cohort competition.

## Decision criteria

| Criterion | Amavita Research | Typical AMC cardiovascular site |
|---|---|---|
| Contract execution | 5–8 weeks first draft to fully executed | 16–36 weeks; multiple legal and OSP reviews |
| Indirect cost rate | None (no F&A overhead) | 25–60% F&A on top of direct costs |
| PI workload | PI dedicates protected time per protocol; not balancing 5+ AMC commitments | PI often splits time across teaching, fellow supervision, multiple protocols, and grants |
| Patient flow | Walk-in cardiology practice; PI is the patient's cardiologist | Specialty clinic referrals + database; PI may not be the patient's primary cardiologist |
| Trial-cohort competition | No same-indication competitors enrolled simultaneously without sponsor approval | AMCs commonly enroll patients into multiple same-indication trials |
| IRB strategy | Central IRB (WCG, Advarra) preferred — days to approval | Local IRB required by many AMCs — 4–8+ weeks |
| Decision authority | Single PI; rapid site-level decisions | OSP, IRB, multi-departmental sign-off |
| Subspecialty depth | Triple-board-certified EP, interventional, structural heart leadership | Strong — but PI access depends on AMC department structure |
| Cross-border designs | Available via bioaccess® (Latin America) | Generally not |

## When to choose Amavita Research

- You need fast contract-to-first-patient timing
- You're cost-sensitive on F&A overhead
- You want a single PI's protected time and decision authority
- You want patient flow from in-network cardiology, not from a specialty referral pipeline

## When an AMC site may fit better

- You need an AMC's specific imaging core lab or research infrastructure
- Your protocol depends on AMC-only patient populations (transplant, complex congenital, etc.)
- Your sponsor program has academic publication and KOL requirements that align with AMC priorities
- You're running translational research adjacent to bench work at the AMC

## Key links

- Discuss your protocol: https://www.amavitaresearch.com/contact-sponsor
- Site capabilities: https://www.amavitaresearch.com/capabilities
- Comparison vs. CRO-owned networks: https://www.amavitaresearch.com/compare/amavita-vs-cro-owned-sites